Dr. Shafi Ullah Khan presents information on migraine including diagnostic criteria, clinical features, classification, pathophysiology, treatment approaches, and future treatment options. Key points include the diagnostic criteria of recurrent headache lasting 4-72 hours with features of nausea/vomiting/photophobia, classification into types such as migraine with and without aura, the trigeminovascular system pathway in migraine pathophysiology, treatment approaches including abortive medications and preventive medications/procedures, and novel emerging treatments under investigation.
1 of 110
More Related Content
Migraine
1. Dr. SHAFI ULLAH KHAN
Resident Internal Medicine
MAW LRH Peshawar
4. Diagnostic Criteria
Recurrent Headache 4 – 72 Hrs.
5 episodes
Normal Physical Examination
1 Of Following
Nausea,Vomiting,Photophobia
Phonophobia
2 Of The Following
Unilateral, Throbbing, Aggrevated
by movements, Moderate to severe
intensity
9. Features Of Migraine Aura
• Precedes or
accompany
• Develops
Over 5 – 20
min
• Lasts Less
than 60 Min
• Visual
Symptoms
common
• Scotoma
• Tunnel vision
• hemianopia
• Complete
Blindness
• Auditory ,
motor,
sensory also
possible.
16. Classification of Migraine
• Migraine With Out Aura
• Probable Migraine With Out
Aura
• Migraine With Aura
• Probable Migraine With
Aura
• Chronic Migraine
• Analgesic Overuse Migraine
• Childhood Periodic
Syndrome (May Not attributed to
Migraine)
• Complications Of Migraine
• Miscellaneous ( Not fitting
above)
24. Lt Side Spontaneous
Migraine
Rt. Side spontaneous
Migraine
• Lateralization to the side of the pain
• DorsoLateral Pons ( Nor adrenergic Locus Ceruleus)
26. Migraine Disability Assessment Score
(MIDAS)
Work
• No of days missed completely_____
• Days where efficiency reduced to half or more___
Household Activity
• Days missed completely____
• Days productivity reduced to half or more___
Social
• No of days social gatherings, leisure activities missed.
29. ID-CM Screening Tool
12 Item screening tool for chronic Migraine (15 days or more in a month)
• 82% sensitive.
• 87 % specific.
• 90% PPV.
Pain moderate or severe ( Frequency)
Clinical features e.g Nausea, vomiting, photophobia ( Frequency)
• How often they worry about missing school, social activity or work.
49. Non Pharmacological Measures
• Implant near occipital nerve
• Pulse generator gluteal muscles,
collar bone.
• Sine 1977ONS
• Age>18 Interruption to hyper
exaggerated response to normal
sensory stimuli.
• Migraine with aura
• Metals, Stimulators, Pacemakers,
Epilepsy Hx.
TMS
50. Complimentary Alternating Medicine
Butter Bur Herb (Petasites Hybridus)
Also called battle dock, bog rhubarb, bogshorn, capdockin
Level A Recommendation From American Headache
Association / American Association Of Neurology AHS/AAN.
Pyrrolizodine Alkaloid(Hepatotoxic) Free (PA Free) Brands
approved by FDA for Migraine management.
54. Trans cranial Electric Nerve Stimulation TENS
CAM continued…..
FDA approved
(2014)
20 minutes a day
Self Adhesive
Electrode in
center
Stimulates
Trigeminal Nerve
TENS Electrodes
with pulse
generator
Contraindication
Pacemakers
Epilepsy
Bath /Shower
55. Body Work ( CAM ….)
CST Acupressure Bowen Technique
66. 5 Don’ts
Performing Neuroimaging in Stable
headaches fulfilling Migraine
Criteria.
Performing CT When MRI available
Except Emergency
Recommending surgical
Deactivation Of Migraine Trigger
Points
67. 5 Don’ts
Prescribing Opioids and
Butalbitals as fine line
treatment for recurrent
migraine headaches.
Recommending prolonged and
frequent use of OTC pain meds
68. When To Do Neuroimaging?
Pattern
Change
First Or
Worst
Age>50
Abnormal
Examination
Epilepsy
Posterior
located
Headaches
New Daily,
persistent
Fever
Worsening
Symptoms
Immunocompr
-omised
74. I Live Away From Hospital?
Self Medication FDA
Approved
Caffeine
Acetami
nophen
Aspirin
75. When To Do Prophylaxis?
Frequency> 2/ Month
MIDAS II or More
Ineffective Symptoms Relief
Duration > 24 Hours
Failed Abortive/ Overuse
Migraine Variants
77. What To Do At Casualty
Combination Therapy
5HT1B/1D Agonists, NSAIDs Dopamine Receptor Agonists
No Opioids Unless Thoroughly Assessed
Migraine Time, Ineffective Cool Compresses over pain site
Minimize Sensory Stimuli
Visual Auditory
78. When To Admit?
• Nausea, Vomiting
• Dehydration
• Status Migranosus
• Refractory Migraine
• Medication Overuse
• (Ergot alkaloids, Opioids, Analgesics)
87. Did You Know?
Serena Williams
Menstrual Migraines
"I'd never heard of
[menstrual migraines]
before, All this time, I
thought it was a
regular migraine.“
Serena Williams
88. Menstrual Migraine
Abortive Same As Non Menstrual
Preventive: Long Acting Triptan
(Fravitriptan)
Hormonal Therapy
Perimenstrual 0.5mg oral Estradiol
1mg Transdermal Patch. 24/4 > 21/7
96. Did You Know?
Every 3rd case Of vertigo is actually migraine and wrongly labeled as vertigo.
• Migraine with neurological symptoms and vertigo and hemiparesis is
called Acephalgic Migraine.
Triptans Don’t work in Aura and should be used when migraine starts.
• Long Acting Triptans are best choice in Menstrual Migraine . Fravitriptan.
97. Did you Know?
27 Billion Euros are spent per annum in Europe
• Good Headache histories are taken not given.
• Migraines can not be cured. Only managed. Inherited tendency.
19.6 Billion USD are spent per year in USA.
In the UK, there are an estimated 190,000 migraine attacks every day
• Migraine is amongst the three most prevalent health conditions
worldwide, along with anemia and hearing loss.
98. Did you Know?
An estimated 25 million days are lost from work or school every year
because of migraine
• one-third of all patients consult because of headache – more than for any
other complaint
Depression is three times more common in people with migraine or severe
headaches than in healthy individuals
• Migraine remains undiagnosed and undertreated in at least 50% of
patients, and less than 50% of migraine patients consult a physician.
107. Reference
• Harrison Principles of internal medicine 19th edition.
• Up-to-date Lippincott Williams and Wilkins
• Medscape
• Mayo clinic Guidelines
• NIH / NHS
• Oxford Textbook Of Internal Medicine
• International Headache association Guidelines
• JAMA , BJM, AAN, FDA.
108. Imitrex (sumatriptan succinate) tablets. Prescribing Information. GlaxoSmithKline.
February 2010. [Full Text].
Imitrex (sumatriptan) Nasal Spray. Prescribing Information. GlaxoSmithKline. February
2010. [Full Text].
Leonardi M, Mathers C. Global burden of migraine in the Year 2000: summary of
methods and data sources. World Health Organization. Available at
http://www.who.int/healthinfo/statistics/bod_migraine.pdf. Accessed March 27, 2013.
Lowry F. Chronic Migraine Responds to OnabotulinumtoxinA. Medscape Medical
News. Available at http://www.medscape.com/viewarticle/825002. Accessed May 19,
2014.
Minson CT, Green DJ. Measures of vascular reactivity: prognostic crystal ball or
Pandora's box?. J Appl Physiol. Aug 2008;105(2):398-9. [Medline].
[Guideline] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E.
Evidence-based guideline update: pharmacologic treatment for episodic migraine
prevention in adults: report of the Quality Standards Subcommittee of the American
Academy of Neurology and the American Headache Society. Neurology. Apr 24
2012;78(17):1337-45. [Medline]. [Full Text].
109. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al.
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind,
randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. Jun
2010;50(6):921-36. [Medline].
Jeffrey S. FDA Approves First Device to Prevent Migraine. Medscape Medical News. Available
at http://www.medscape.com/viewarticle/821810. Accessed March 17, 2014.
Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular
dihydroergotamine and metoclopramide for acute treatment of migraine headache.
Headache. Nov-Dec 2001;41(10):976-80. [Medline].
Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a
randomized controlled trial. Neurology. Oct 26 2010;75(17):1527-32. [Medline].
De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral
contraceptives in women with menstrual migraine without aura. Fertil Steril. Oct
2011;96(4):917-20. [Medline].
von Peter S, Ting W, Scrivani S, Korkin E, Okvat H, Gross M, et al. Survey on the use of
complementary and alternative medicine among patients with headache syndromes.
Cephalalgia. Jun 2002;22(5):395-400. [Medline].
110. Misra UK, Kalita J, Bhoi SK. Allodynia in Migraine: Clinical Observation and Role of
Prophylactic Therapy. Clin J Pain. Jan 16 2013;[Medline].
[Guideline] Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E.
Evidence-based guideline update: NSAIDs and other complementary treatments for
episodic migraine prevention in adults: report of the Quality Standards
Subcommittee of the American Academy of Neurology and the American Headache
Society. Neurology. Apr 24 2012;78(17):1346-53. [Medline]. [Full Text].
Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits
of quetiapine for the prevention of migraine refractory to the combination of
atenolol, nortriptyline, and flunarizine. Pain Med. Jan 2010;11(1):48-52. [Medline].
Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate
for migraine prevention: a randomized controlled trial. JAMA. Feb 25
2004;291(8):965-73. [Medline].
Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of
gabapentin in migraine prophylaxis. Headache. Feb 2001;41(2):119-28. [Medline].
Jeffrey S. FDA Okays First Drug for Migraine Prevention in Adolescents. Medscape
Medical News [serial online]. Mar 28 2014;Accessed Apr 8 2014. Available at
http://www.medscape.com/viewarticle/822748.